J&J says Caplyta met main goal in bipolar mania late-stage study
Johnson & Johnson said its experimental Caplyta use for bipolar mania met the main goal of a late-stage study, bringing the drug a step closer to potential expansion beyond approved uses. Caplyta was acquired through J&J’s $14.6 billion acquisition of Intra-Cellular Therapies.
Johnson & Johnson said on Monday its experimental use of Caplyta for bipolar mania met the main goal of a late-stage study, bringing the drug a step closer to expanding beyond its currently approved uses. 6 billion acquisition of Intra-Cellular Therapies.